Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
Erin L. Martin, Justin C. Strickland, Nicolas J. Schlienz, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis
Tory R. Spindle, C. Austin Zamarripa, Ethan B. Russo, et al.
Drug and Alcohol Dependence (2024) Vol. 257, pp. 111267-111267
Closed Access | Times Cited: 11
Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study
Lara Bapir, Simon Erridge, Martha Nicholas, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 3, pp. 281-295
Open Access | Times Cited: 18
A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders
Oluwadara Pelumi Omotayo, Yolandy Lemmer, Shayne Mason
Journal of Cannabis Research (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 6
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Brandon Richardson, Andrew J. Macpherson, Francis Rodriguez Bambico
Brain Behavior & Immunity - Health (2022) Vol. 26, pp. 100554-100554
Open Access | Times Cited: 25
Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry
Sajed Mangoo, Simon Erridge, Carl Holvey, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 11-12, pp. 995-1008
Open Access | Times Cited: 25
Synthetic surprise as the foundation of the psychedelic experience
Roberto De Filippo, Dietmar Schmitz
Neuroscience & Biobehavioral Reviews (2024) Vol. 157, pp. 105538-105538
Open Access | Times Cited: 4
Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials
Martina D’Angelo, Luca Steardo
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3603-3603
Open Access | Times Cited: 4
Cannabis: Zone Aspects of Raw Plant Components in Sport—A Narrative Review
Corina Flangea, Mihaela Vlad, Roxana Popescu, et al.
Nutrients (2025) Vol. 17, Iss. 5, pp. 861-861
Open Access
Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry
Manaswini Pillai, Simon Erridge, Lara Bapir, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 11-12, pp. 1009-1018
Open Access | Times Cited: 18
A survey of medical cannabis use during perimenopause and postmenopause
Mary Kathryn Dahlgren, Celine El-Abboud, Ashley M. Lambros, et al.
Menopause The Journal of The North American Menopause Society (2022) Vol. 29, Iss. 9, pp. 1028-1036
Open Access | Times Cited: 16
In Vitro Effects of Cannabidiol on Activated Immune–Inflammatory Pathways in Major Depressive Patients and Healthy Controls
Muanpetch Rachayon, Ketsupar Jirakran, Pimpayao Sodsai, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 4, pp. 405-405
Open Access | Times Cited: 15
Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviours
Michaël Maes, Muanpetch Rachayon, Ketsupar Jirakran, et al.
Acta Neuropsychiatrica (2023) Vol. 36, Iss. 5, pp. 287-298
Open Access | Times Cited: 8
Cannabinoids: Emerging sleep modulator
Zhen Xuen Brandon Low, Xin Ru Lee, Tomoko Soga, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115102-115102
Open Access | Times Cited: 7
Should oncologists trust cannabinoids?
Ioana Creangă-Murariu, Leontina Elena Filipiuc, Magdalena Cuciureanu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Self-reported Medicinal Cannabis Use as an Alternative to Prescription and Over-the-counter Medication Use Among US Military Veterans
Marion McNabb, Katherine A. Durante, Sarah Trocchio, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 6, pp. 562-577
Open Access | Times Cited: 6
Online survey of medicinal cannabis users: Qualitative analysis of patient-level data
Albert Garcia‐Romeu, Joshua S. Elmore, Rhiannon E. Mayhugh, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
Cannabis-based medicinal products (CBMPs) for the treatment of Long COVID symptoms: current and potential applications
Hannah Thurgur, Anne Katrin Schlag, Elizabeth Iveson, et al.
Exploration of Medicine (2023), pp. 487-503
Open Access | Times Cited: 4
Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial
Michael J. Telch, Caitlin M. Fischer, Eric D. Zaizar, et al.
Contemporary Clinical Trials (2022) Vol. 122, pp. 106933-106933
Closed Access | Times Cited: 7
Cannabis use amongst tinnitus patients: consumption patterns and attitudes
Dorsa Mavedatnia, Marc Levin, Jong Wook Lee, et al.
Journal of Otolaryngology - Head and Neck Surgery (2023) Vol. 52, Iss. 1
Open Access | Times Cited: 3
Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviors: effects of in vitro cannabidiol administration
Michael Maes, Muanpetch Rachayon, Ketsupar Jirakran, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Baseline affective symptomatology moderates acute subjective effects of high potency THC and CBD cannabis concentrates.
Renée Martin‐Willett, Carillon J. Skrzynski, Hollis C. Karoly, et al.
Experimental and Clinical Psychopharmacology (2023) Vol. 31, Iss. 6, pp. 1039-1049
Closed Access | Times Cited: 2
Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19—A Scoping Review
Cassidy Scott, Stefan Hall, Juan Zhou, et al.
Journal of Clinical Medicine (2023) Vol. 13, Iss. 1, pp. 227-227
Open Access | Times Cited: 2
Effects of cannabidiol on activated immune-inflammatory pathways in major depressive patients and healthy controls
Muanpetch Rachayon, Ketsupar Jirakran, Pimpayao Sodsai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Uso de Cannabis para tratamento da dor crônica: uma revisão sistemática
Gabriel Ferreira Setton Matias, Maria Adriely Cunha Lima, Tiago Almeida Costa, et al.
Research Society and Development (2022) Vol. 11, Iss. 3, pp. e25411326586-e25411326586
Open Access | Times Cited: 4
Exploring medicinal use of low-THC cannabis products - Comparing experienced effects and side-effects between CBD-oil-only users to users of high-THC cannabis products
Sinikka L. Kvamme, Michael Mulbjerg Pedersen, Kristine Rømer Thomsen, et al.
Drugs Education Prevention and Policy (2024), pp. 1-13
Open Access
Page 1 - Next Page

Scroll to top